Kartik Chandran

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7292005/publications.pdf

Version: 2024-02-01

132 papers	10,556 citations	41323 49 h-index	37183 96 g-index
159 all docs	159 docs citations	159 times ranked	13652 citing authors

#	Article	IF	Citations
1	Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science, 2022, 375, 104-109.	6.0	15
2	Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes. PLoS Computational Biology, 2022, 18, e1009778.	1.5	10
3	Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies. Cell Host and Microbe, 2022, 30, 248-259.e6.	5.1	11
4	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine, 2022, 182, 115.	2.6	63
5	Reovirus infection is regulated by NPC1 and endosomal cholesterol homeostasis. PLoS Pathogens, 2022, 18, e1010322.	2.1	11
6	Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Science Translational Medicine, 2022, 14, eabl5399.	5.8	16
7	Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naÃ¯ve and previously infected individuals. EBioMedicine, 2022, 78, 103972.	2.7	31
8	A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice. PLoS Pathogens, 2022, 18, e1010573.	2.1	6
9	Generation of plasma cells and CD27^{â^'}IgD^{â^'} B cells during hantavirus infection is associated with distinct pathological findings. Clinical and Translational Immunology, 2021, 10, e1313.	1.7	7
10	Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation. MBio, 2021, 12, .	1.8	6
11	Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC. JCI Insight, 2021, 6, .	2.3	36
12	A Glycoprotein Mutation That Emerged during the 2013â€“2016 Ebola Virus Epidemic Alters Proteolysis and Accelerates Membrane Fusion. MBio, 2021, 12, .	1.8	9
13	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. Journal of Virology, 2021, 95, .	1.5	6
14	Approaching the Interpretation of Discordances in SARS-CoV-2 Testing. Open Forum Infectious Diseases, 2021, 8, ofab144.	0.4	2
15	The shape of pleomorphic virions determines resistance to cell-entry pressure. Nature Microbiology, 2021, 6, 617-629.	5.9	29
16	Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. MSphere, 2021, 6, .	1.3	11
17	MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage. Journal of Molecular Biology, 2021, 433, 166896.	2.0	7
18	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Qualitative Immunoglobulin G Assays: The Value of Numeric Reporting. Archives of Pathology and Laboratory Medicine, 2021, 145, 929-936.	1.2	1

#	Article	IF	Citations
19	Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell, 2021, 184, 3486-3501.e21.	13.5	39
20	Genetic depletion studies inform receptor usage by virulent hantaviruses in human endothelial cells. ELife, 2021, 10, .	2.8	13
21	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	0.9	62
22	Tracing Transmission of Sin Nombre Virus and Discovery of Infection in Multiple Rodent Species. Journal of Virology, 2021, 95, e0153421.	1.5	14
23	Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	12
24	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega, 2021, 6, 85-102.	1.6	54
25	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. MBio, 2021, 12, e0247321.	1.8	35
26	Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity. Frontiers in Immunology, 2021, 12, 729851.	2.2	5
27	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. Nature Communications, 2021, 12, 6853.	5.8	41
28	Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science, 2021, , eabl6502.	6.0	2
29	The Hantavirus Surface Glycoprotein Lattice and Its Fusion Control Mechanism. Cell, 2020, 183, 442-456.e16.	13.5	52
30	Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6675-6685.	3.3	80
31	Oral Vaccination With Recombinant Vesicular Stomatitis Virus Expressing Sin Nombre Virus Glycoprotein Prevents Sin Nombre Virus Transmission in Deer Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, 333.	1.8	7
32	Neutralizing Antibodies against Crimeanâ€“Congo Hemorrhagic Fever Virus Derived from a Human Survivor. Proceedings (mdpi), 2020, 50, .	0.2	0
33	HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses. Science Immunology, 2020, 5, .	5.6	12
34	Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Science Translational Medicine, 2020, 12, .	5.8	298
35	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	0.9	184
36	Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. Journal of Virology, 2020, 94, .	1.5	28

#	Article	IF	Citations
37	Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 2020, 369, 731-736.	6.0	534
38	Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmetteâ€“GuÃ©rin Vaccination to Improve Antiviral Antibody Responses. Journal of Immunology, 2020, 205, 425-437.	0.4	3
39	A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition. Journal of Virology, 2020, 94, .	1.5	7
40	Mapping the Interface between New World Hantaviruses and Their Receptor, PCDH1. Proceedings (mdpi), 2020, 50, .	0.2	0
41	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host and Microbe, 2020, 28, 486-496.e6.	5.1	178
42	Meeting report: Eleventh International Conference on Hantaviruses. Antiviral Research, 2020, 176, 104733.	1.9	8
43	Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding. PLoS Biology, 2020, 18, e3000626.	2.6	59
44	Development of an antibody cocktail for treatment of Sudan virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3768-3778.	3.3	23
45	Site-Specific Photo-Crosslinking Proteomics Reveal Regulation of IFITM3 Trafficking and Turnover by VCP/p97 ATPase. Cell Chemical Biology, 2020, 27, 571-585.e6.	2.5	27
46	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Cell Host and Microbe, 2020, 27, 963-975.e5.	5.1	23
47	Real-Time Analysis of Individual Ebola Virus Glycoproteins Reveals Pre-Fusion, Entry-Relevant Conformational Dynamics. Viruses, 2020, 12, 103.	1.5	16
48	Accelerated viral dynamics in bat cell lines, with implications for zoonotic emergence. ELife, 2020, 9, .	2.8	91
49	Title is missing!. , 2020, 18, e3000626.		0
50	Title is missing!. , 2020, 18, e3000626.		0
51	Title is missing!. , 2020, 18, e3000626.		0
52	Title is missing!. , 2020, 18, e3000626.		0
53	Title is missing!. , 2020, 18, e3000626.		0
54	Title is missing!. , 2020, 18, e3000626.		0

#	Article	IF	Citations
55	A Hyperstabilizing Mutation in the Base of the Ebola Virus Glycoprotein Acts at Multiple Steps To Abrogate Viral Entry. MBio, 2019, 10, .	1.8	11
56	Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses. Viruses, 2019, 11, 645.	1.5	18
57	Human, Nonhuman Primate, and Bat Cells Are Broadly Susceptible to Tibrovirus Particle Cell Entry. Frontiers in Microbiology, 2019, 10, 856.	1.5	8
58	Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. PLoS Pathogens, 2019, 15, e1008061.	2.1	35
59	Hantavirus entry: Perspectives and recent advances. Advances in Virus Research, 2019, 104, 185-224.	0.9	65
60	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	0.9	70
61	Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. Npj Vaccines, 2019, 4, 5.	2.9	45
62	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	0.9	224
63	Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nature Structural and Molecular Biology, 2019, 26, 204-212.	3.6	30
64	Two Point Mutations in Old World Hantavirus Glycoproteins Afford the Generation of Highly Infectious Recombinant Vesicular Stomatitis Virus Vectors. MBio, 2019, 10, .	1.8	26
65	Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Cell Host and Microbe, 2019, 25, 39-48.e5.	5.1	83
66	A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Cell Host and Microbe, 2019, 25, 49-58.e5.	5.1	82
67	IFITM3 directly engages and shuttles incoming virus particles to lysosomes. Nature Chemical Biology, 2019, 15, 259-268.	3.9	169
68	Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. Journal of Biological Chemistry, 2018, 293, 6201-6211.	1.6	7
69	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	0.9	153
70	Ebola virus, but not Marburg virus, replicates efficiently and without required adaptation in snake cells. Virus Evolution, 2018, 4, vey034.	2.2	3
71	Protocadherin-1 is essential for cell entry by New World hantaviruses. Nature, 2018, 563, 559-563.	13.7	84
72	The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nature Microbiology, 2018, 3, 1084-1089.	5.9	283

#	Article	IF	Citations
73	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5.	5.1	182
74	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173
75	A naturally occurring antiviral ribonucleotide encoded by the human genome. Nature, 2018, 558, 610-614.	13.7	225
76	Candidate medical countermeasures targeting Ebola virus cell entry. Future Virology, 2017, 12, 119-140.	0.9	1
77	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	0.9	173
78	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.	13.5	145
79	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell, 2017, 169, 891-904.e15.	13.5	103
80	Structural basis for antibody-mediated neutralization of Lassa virus. Science, 2017, 356, 923-928.	6.0	170
81	Generation and characterization of protective antibodies to Marburg virus. MAbs, 2017, 9, 696-703.	2.6	28
82	Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody. Immunology Letters, 2017, 190, 289-295.	1.1	2
83	Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses. Viruses, 2017, 9, 106.	1.5	22
84	How to turn competitors into collaborators. Nature, 2017, 541, 283-285.	13.7	3
85	A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. MSphere, 2016, 1, .	1.3	25
86	Taxonomy of the order Mononegavirales: update 2016. Archives of Virology, 2016, 161, 2351-2360.	0.9	407
87	Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway. MBio, 2016, 7, e01857-15.	1.8	66
88	A â€œTrojan horseâ€•bispecific-antibody strategy for broad protection against ebolaviruses. Science, 2016, 354, 350-354.	6.0	101
89	Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. MBio, 2016, 7, e02154-15.	1.8	86
90	Possibility and Challenges of Conversion of Current Virus Species Names to Linnaean Binomials. Systematic Biology, 2016, 66, syw096.	2.7	17

#	Article	IF	Citations
91	Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Scientific Reports, 2016, 6, 19193.	1.6	27
92	A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry. Molecular Therapy - Nucleic Acids, 2016, 5, e321.	2.3	41
93	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	2.9	80
94	Cysteine Cathepsin Inhibitors as Anti-Ebola Agents. ACS Infectious Diseases, 2016, 2, 173-179.	1.8	33
95	Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. MBio, 2015, 6, e00801.	1.8	100
96	FILOVIRUS ENTRY INTO SUSCEPTIBLE CELLS. , 2015, , 487-514.		4
97	Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis In Vivo. MBio, 2015, 6, e00565-15.	1.8	65
98	Novel Small Molecule Entry Inhibitors of Ebola Virus. Journal of Infectious Diseases, 2015, 212, S425-S434.	1.9	49
99	Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. ELife, 2015, 4, .	2.8	110
100	Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Archives of Virology, 2014, 159, 1229-37.	0.9	59
101	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	1.5	49
102	Structural Characterization of the Glycoprotein GP2 Core Domain from the CAS Virus, a Novel Arenavirus-Like Species. Journal of Molecular Biology, 2014, 426, 1452-1468.	2.0	25
103	Discussions and decisions of the 2012â€“2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012â€“June 2013. Archives of Virology, 2014, 159, 821-830.	0.9	85
104	Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge. ACS Chemical Biology, 2014, 9, 2263-2273.	1.6	23
105	Comprehensive Functional Analysis of N-Linked Glycans on Ebola Virus GP1. MBio, 2014, 5, e00862-13.	1.8	93
106	Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemannâ€“Pick C1. Virology, 2014, 468-470, 637-646.	1.1	55
107	A Proteolytic Cascade Controls Lysosome Rupture and Necrotic Cell Death Mediated by Lysosome-Destabilizing Adjuvants. PLoS ONE, 2014, 9, e95032.	1.1	29
108	C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: Effects of conjugation to cholesterol and side chainâ€“side chain crosslinking. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5356-5360.	1.0	33

#	Article	IF	Citations
109	Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 1425-1432.	0.9	54
110	Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 301-311.	0.9	99
111	Conformational Properties of Peptides Corresponding to the Ebolavirus GP2 Membrane-Proximal External Region in the Presence of Micelle-Forming Surfactants and Lipids. Biochemistry, 2013, 52, 3393-3404.	1.2	8
112	Cathepsin-mediated Necrosis Controls the Adaptive Immune Response by Th2 (T helper type 2)-associated Adjuvants. Journal of Biological Chemistry, 2013, 288, 7481-7491.	1.6	66
113	A Mutation in the Ebola Virus Envelope Glycoprotein Restricts Viral Entry in a Host Species- and Cell-Type-Specific Manner. Journal of Virology, 2013, 87, 3324-3334.	1.5	36
114	Structural Basis for Differential Neutralization of Ebolaviruses. Viruses, 2012, 4, 447-470.	1.5	63
115	Niemann-Pick C1 (NPC1)/NPC1-like1 Chimeras Define Sequences Critical for NPC1â€™s Function as a Filovirus Entry Receptor. Viruses, 2012, 4, 2471-2484.	1.5	36
116	Endocytic Pathways Involved in Filovirus Entry: Advances, Implications and Future Directions. Viruses, 2012, 4, 3647-3664.	1.5	15
117	Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO Journal, 2012, 31, 1947-1960.	3.5	284
118	Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences. Journal of Virology, 2012, 86, 3284-3292.	1.5	114
119	Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein. ChemBioChem, 2012, 13, 2549-2557.	1.3	26
120	Crystal Structure of the Marburg Virus GP2 Core Domain in Its Postfusion Conformation. Biochemistry, 2012, 51, 7665-7675.	1.2	37
121	Marburg Virus Glycoprotein GP2: pH-Dependent Stability of the Ectodomain Î±-Helical Bundle. Biochemistry, 2012, 51, 2515-2525.	1.2	35
122	Filovirus entry into cells â€“ new insights. Current Opinion in Virology, 2012, 2, 206-214.	2.6	73
123	Small molecule inhibitors reveal Niemannâ€“Pick C1 is essential for Ebola virus infection. Nature, 2011, 477, 344-348.	13.7	601
124	Ebola virus entry requires the cholesterol transporter Niemannâ€“Pick C1. Nature, 2011, 477, 340-343.	13.7	1,127
125	The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology, 2011, 419, 72-83.	1.1	118
126	Designed protein mimics of the Ebola virus glycoprotein GP2 Î±â€helical bundle: Stability and pH effects. Protein Science, 2011, 20, 1587-1596.	3.1	41

#	Article	IF	Citations
127	A shared structural solution for neutralizing ebolaviruses. Nature Structural and Molecular Biology, 2011, 18, 1424-1427.	3.6	113
128	Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes. Journal of Biological Chemistry, 2011, 286, 15854-15861.	1.6	59
129	A Forward Genetic Strategy Reveals Destabilizing Mutations in the Ebolavirus Glycoprotein That Alter Its Protease Dependence during Cell Entry. Journal of Virology, 2010, 84, 163-175.	1.5	136
130	Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection. Science, 2005, 308, 1643-1645.	6.0	744
131	Complete In Vitro Assembly of the Reovirus Outer Capsid Produces Highly Infectious Particles Suitable for Genetic Studies of the Receptor-Binding Protein. Journal of Virology, 2001, 75, 5335-5342.	1.5	52
132	Structural Basis of Neutralization by Human Antibodies Targeting Crimean-Congo Hemorrhagic Fever Virus Glycoprotein Gc. SSRN Electronic Journal, 0, , .	0.4	0